

In re Application of: M. WADA et al. Serial No.: 10/076,421 Group Art Unit: 1614 Filed: February 19, 2002 Examiner: TBA For: ANTI-HIV AGENTS INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 Assistant Commissioner for Patents I hereby certify that this correspondence is being deposited Washington, D. C. 20231 with the U.S. Postal Services as First Class Mail in an envelope addressed To: Commissioner of Patents/and/Trademarks. Washington, D.C. 20231 On: Sir: Signature: CITED MATERIALS Applicant(s) hereby disclose the information listed in the attached form PTO-1449. Copies of materials listed but not attached were cited in parent application Serial No. ____; see 37 C.F.R. § 1.98(d). Copies of materials listed but not attached were cited in an International Search Report dated _____; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed _ ADDITIONAL INFORMATION [NONE?] **LANGUAGE** All listed materials are in the English language; see 37 C.F.R. § 1.98. Non-English language references: The reference(s): in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): , respectively. (An) English-language translation(s) of the references: provided. A commercial English-language abstract of reference(s) is (are) provided.

	An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).
<u>FEES</u>	
⊠ `	No fee is required for this Information Disclosure Statement because:
	This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
	This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
	☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
0	A fee is required for this Information Disclosure Statement:
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).
•• •	This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.
CERT	<u>IFICATION</u>
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
0	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of § . However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Nicole E. Kinsey (Reg. No. 50/123) Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

FILED: October 28, 2002

K:\hayak\9\IDS.dot



Please type a paus sign (+) insertains box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449A/PTO)	•		Complete if Known
				Application Number	10/076,421
INFO	DRMATION	DIS	CLOSURE	Filing Date	February 19, 2002
STA	TEMENT B'	Y A	PPLICANT	First Named Inventor	M. WADA et al.
				Group Art Unit	1614
	(use as many she	ets as	necessary)	Examiner Name	TBA
Sheet	1	of	2	Attorney Docket Number	HAYAK 9

	U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	U.S. Pa	atent Documen	Name of Patentes of Apprount	Date of Publication of	Pages, Columns, Lines, Where Relevan			
		arminer Cito Rials No. 1		Kind Cade (if known)	af Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		
	AA								
	AB								
	AC								
	AD					· · · · · · · · · · · · · · · · · · ·			
	AE								
	AF			·		<u> </u>			
	AG								
	AH								
	Ai								
	Ą								
	AK								
	AL					·			
	AM								
	AN								
	AO		·						
	AP								
	AQ					·			
	AR								

FOREIGN PATENT DOCUMENTS									
Examin er Initials*	Cite No.1	Office ³	reign Patent Docum	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τg	
	AS	WIPO	96/13160		5/9/96				
	ΑŤ	WIPO	02/09753A1		2/7/02		-		
								ļ	
			·		·				
					•				

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, OC 20231. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTC	,		Complete if Known			
			01.001155	Application Number	10/076,421		
			CLOSURE	Filing Date	February 19, 2002		
STAT	TEMENT B	YA	PPLICANT	First Named Inventor	M. WADA et al.		
				Group Art Unit	1614		
	(use as many she	ets es	necessary)	Examiner Name	TBA		
Sheet	2	of	2	Attorney Docket Number	HAYAK 9		

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
	BA	Wada et al., "Amino-Terminal Fragment of Urokinase-Type Plasminogen Activator Inhibits HIV-1 Replication," Biochemical and Biophysical Research Communications, Vol. 284, No. 2, June 8, 2001 (348-351)						
			,					
•								
	,							
	·							
								

Examiner Signature	Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.